Sökning: WFRF:(Kesäniemi Y Antero) >
High sensitivity C ...
High sensitivity C reactive protein as a prognostic marker in patients with mild to moderate aortic valve stenosis during lipid-lowering treatment : an SEAS substudy
-
Blyme, Adam (författare)
-
Asferg, Camilla (författare)
-
Nielsen, Olav W (författare)
-
visa fler...
-
Sehestedt, Thomas (författare)
-
Kesäniemi, Y Antero (författare)
-
Gohlke-Bärwolf, Christa (författare)
-
- Boman, Kurt (författare)
- Umeå universitet,Medicin,Skellefteå Research Unit
-
- Willenheimer, Ronnie (författare)
- Lund University,Lunds universitet,Kardiologiska klinikens forskargrupp,Forskargrupper vid Lunds universitet,Cardiology Research Group,Lund University Research Groups
-
Ray, Simon (författare)
-
Nienaber, Christoph A (författare)
-
Rossebø, Anne (författare)
-
Wachtell, Kristian (författare)
-
Olsen, Michael H (författare)
-
visa färre...
-
(creator_code:org_t)
- 2015-02-04
- 2015
- Engelska.
-
Ingår i: Open heart. - : BMJ. - 2053-3624. ; 2:1
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://umu.diva-por... (primary) (Raw object)
-
https://openheart.bm...
-
https://portal.resea... (primary) (free)
-
http://www.ncbi.nlm....
-
http://dx.doi.org/10...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- AIMS: To assess the prognostic importance of high-sensitive C reactive protein (hsCRP) in patients with mild to moderate aortic valve stenosis during placebo or simvastatin/ezetimibe treatment in Simvastatin and Ezetimibe in Aortic Stenosis (SEAS).METHODS AND RESULTS: In 1620 SEAS patients, we measured lipids and hsCRP at baseline and after 1 year of treatment and registered during 4 years of follow-up major cardiovascular events (MCE) composed of ischaemic cardiovascular events (ICE) and aortic valve-related events (AVE). Simvastatin/ezetimibe reduced low-density lipoprotein cholesterol (3.49 (2.94 to 4.15) to 1.32 (1.02 to 1.69) vs 3.46 (2.92 to 4.08) to 3.34 (2.81 to 3.92) mmol/L) and hsCRP (2.1 (0.9 to 4.1) to 1.2 (0.6 to 2.4) vs 2.2 (0.9 to 4.9) to 1.8 (0.85 to 4.35) mg/L, all p<0.05) during the first year of treatment. In multivariable Cox regression analysis adjusting for traditional risk factors and baseline hsCRP, ICE was associated with a 1-year increase of hsCRP (HR=1.19 (95% CI 1.12 to 1.25), p<0.001) but not with active treatment (HRTreatment=0.86 (0.67 to 1.13), p=0.28). Patients in the top quartile of baseline hsCRP versus the rest were associated with a higher risk of MCE (HR=1.34(1.09 to 1.64), p=0.02). The prognostic benefit of reduction in hsCRP after 1 year was significantly larger (p<0.01 for interaction) in patients with high versus low baseline hsCRP; hence, a reduction in hsCRP abolished the difference in incidence of MCE between high versus low baseline hsCRP in patients with reduced hsCRP (31.1 vs 31.9%, NS) in contrast to patients with increased hsCRP.CONCLUSIONS: The treatment-associated reduction in ICE was in part related to a reduction in hsCRP but not in lipids. hsCRP reduction was associated with less MCE, especially in patients with high baseline hsCRP.TRIAL REGISTRATION: NCT00092677.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Blyme, Adam
-
Asferg, Camilla
-
Nielsen, Olav W
-
Sehestedt, Thoma ...
-
Kesäniemi, Y Ant ...
-
Gohlke-Bärwolf, ...
-
visa fler...
-
Boman, Kurt
-
Willenheimer, Ro ...
-
Ray, Simon
-
Nienaber, Christ ...
-
Rossebø, Anne
-
Wachtell, Kristi ...
-
Olsen, Michael H
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Open heart
- Av lärosätet
-
Umeå universitet
-
Lunds universitet